Cannabinoid-Based Drugs Seek New High, Part II

“Quite Compelling Results”

“We had quite compelling results, which behoove us to continue with a Phase IIB, and then go to Phase III, which also gives us the hope that we will also be successful in inflammatory bowel disease, Crohn’s disease, and also with colitis,” AXIM CEO George E. Anastassov, M.D., D.D.S., told GEN.

AXIM’s development pipeline includes MedChew Rx®, a gum combining CBD and THC that will undergo clinical trials for pain and spasticity associated with Multiple Sclerosis (MS). MedChew Rx will use a methodology the company developed for extracting and purifying

...read more at https://www.genengnews.com/gen-exclusives/cannabinoid-based-drugs-seek-new-high-part-ii/77901111